Amphastar Pharmaceuticals (AMPH) PT Lowered to $22 at BMO Capital
Tweet
Share
E-mail
Get Alerts AMPH Hot Sheet
Price: $21.34 +2.30%
Rating Summary:
2 Buy, 8 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 16 | New: 37
Rating Summary:
2 Buy, 8 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 16 | New: 37
Join SI Premium – FREE
BMO Capital analyst Gary Nachman lowered the price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $22.00 (from $23.00) while maintaining a Market Perform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gartner (IT) PT Lowered to $206 at BMO Capital, adjusting estimates
- Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $42 at Mizuho
- CrowdStrike (CRWD) PT Raised to $250 at Benchmark Ahead of Q2 Results
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
